

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Investigate the effect of fluoxetine and Citalopram on motor performance after stroke in acute stroke patients

#### Protocol summary

##### Study aim

Determining the effect of citalopram and fluoxetine on motor performance after stroke in acute cerebral stroke patients

##### Design

Randomized double-arm, double-blind, placebo-controlled

##### Settings and conduct

acute cerebral stroke patients

##### Participants/Inclusion and exclusion criteria

inclusion: age>18 Fugl-Meyer score<55 motor or sensory paralysis of half of the body after the first episode of acute stroke exclusion : Age over 70 years 2. National Institute of Health stroke score above 15 3. Previous disabilities including lack of speech, cognitive, and movement disorders caused by stroke or any disease of the cerebral cortex. 4. Pregnancy or breastfeeding 5. Current use of anti-depressant drugs 6. Kidney failure (glomerular filtration rate below 30 ml per minute) 7. Abnormal liver function tests 8. Hyponatremia and long TQ distance in the heart strip 9. Restlessness, increased pressure, or other manifestations of serotonin syndrome (after starting treatment)

##### Intervention groups

group A: The participants will receive a capsule containing 20 mg of fluoxetine orally once a day for 90 days, along with one hour of physiotherapy sessions a day, five days a week, for 21 weeks. Intervention group B: The participants will receive a capsule containing 20 mg of citalopram orally once a day for 90 days, along with physiotherapy for one hour a day, five days a week, for 21 weeks. Control group: Participants will receive a capsule containing microcrystalline cellulose as a placebo once a day for 90 days and physiotherapy for one hour a day, five days a week, for 21 weeks.

##### Main outcome variables

in the upper limb (shoulder flexion 90 to 180 degrees - grasping - pronation and supination of the hand - wrist flexion and extension, elbow extension - shoulder

raising) in the lower limb (standing on one leg - knee flexion while standing, sitting - dorsiflexion of the leg - plantar flexion of the leg - hip flexion)

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20220810055657N1**

Registration date: **2022-09-03, 1401/06/12**

Registration timing: **registered\_while\_recruiting**

Last update: **2022-09-03, 1401/06/12**

Update count: **0**

##### Registration date

2022-09-03, 1401/06/12

##### Registrant information

##### Name

Vahid Dehghani MObarake

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 990 154 5294

##### Email address

dehghani-v@kaums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2022-03-21, 1401/01/01

##### Expected recruitment end date

2023-03-20, 1401/12/29

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**  
empty

**Scientific title**  
Investigate the effect of fluoxetine and Citalopram on motor performance after stroke in acute stroke patients

**Public title**  
Investigate the effect of fluoxetine and Citalopram on motor performance after stroke in acute stroke patients

**Purpose**  
Treatment

**Inclusion/Exclusion criteria**  
**Inclusion criteria:**  
Over 18 years old motor or sensory paralysis of half of the body following the first episode of acute stroke (within the last 24 hours), cerebral ischemia Vogel-Meyer motor score below 55  
**Exclusion criteria:**  
Age over 70 years National Institute of Health stroke score above 15 Previous disabilities include: lack of speech, cognitive and movement disorders caused by stroke or any disease of the cerebral cortex. Pregnancy or breastfeeding Current use of antidepressants Kidney failure (glomerular filtration rate below 30 ml per minute) Abnormal liver function tests Hyponatremia and long QT interval in heart strip Restlessness, increased pressure or other manifestations of serotonin syndrome (after starting treatment)

**Age**  
From **18 years** old to **70 years** old

**Gender**  
Both

**Phase**  
3

**Groups that have been masked**

- Participant
- Investigator

**Sample size**  
Target sample size: **90**

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**  
The method of randomization will be as follows: using the block randomization method (permuted block randomization) in such a way that first all 4 combinations of letters A and B are written (6 blocks) and numbers 1 to 6 for each block. considered and by randomly choosing numbers 1 to 6 from the table of random numbers; Its corresponding blocks will be written. This process of selection continues until the number of letters A and B reaches the required number of samples. After entering the study and completing the written consent form, the patient will receive a numerical code from 1 to 100 and from the table Prepared, which is available to the project manager, corresponding to the numerical code assigned to one of the drugs A or B. A and B groups will be randomly assigned to either fluoxetine or citalopram. It should be noted that regarding the variables of primary disability severity and other factors

affecting the functional score, given that this study will be a clinical trial, randomization can largely control known or unknown confounding factors. (Due to the large sample size) statistical modeling also controls the effect of these factors on the outcome of the disease.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

To blind, both drugs are in the form of capsules and will be filled and coded by the neurology resident in bottles that are identical in appearance; these codes will be entered into a table and will be decoded only after the end of the study, so the patient and The doctor will not know the type of medicine received and the treatment group.

**Placebo**

Used

**Assignment**

Parallel

**Other design features**

**Secondary Ids**

empty

**Ethics committees**

**1**

**Ethics committee**

**Name of ethics committee**

Research Ethics Committee, School of Medicine and Dentistry, Kashan University of Medical Sciences

**Street address**

Qutb Rawandi Blvd

**City**

kashan

**Province**

Isfahan

**Postal code**

8715981151

**Approval date**

2021-11-16, 1400/08/25

**Ethics committee reference number**

IR.KAUMS.MEDNT.REC.1400.117

**Health conditions studied**

**1**

**Description of health condition studied**

Acute stroke

**ICD-10 code**

I63.9

**ICD-10 code description**

Cerebral infarction, unspecified

**Primary outcomes**

**1**

**Description**

Motor function after acute stroke in patients

dehghani-v@kaums.ac.ir

### Timepoint

On the 90th day from the beginning of the study

### Method of measurement

Fugl-Meyer movement scale

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Control group: Participants will receive capsules containing microcrystalline cellulose as a placebo orally once a day for 90 days along with physical therapy one hour a day, 5 days a week, for 21 weeks.

#### Category

Placebo

### 2

#### Description

Intervention group: A. Participants will receive capsules containing 20 mg of fluoxetine orally once daily for 90 days, along with physical therapy sessions of one hour per day, 5 days per week, for 21 weeks.

#### Category

Treatment - Drugs

### 3

#### Description

Intervention group: B . Participants will receive capsules containing 20 mg of citalopram orally once daily for 90 days along with physical therapy 1 hour per day, 5 days per week, for 21 weeks.

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Shahid Beheshti Hospital, Kashan

##### Full name of responsible person

Dr. Vahid Dehghani

##### Street address

Qutb Rawandi Blvd

##### City

kashan

##### Province

Isfahan

##### Postal code

87159-81151

##### Phone

+98 990 154 5294

##### Email

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Kashan University of Medical Sciences

##### Full name of responsible person

دکتر علی مسعود

##### Street address

Qutb Rawandi Blvd

##### City

kashan

##### Province

Isfahan

##### Postal code

81151-87159

##### Phone

+98 31 5558 9007

##### Email

dehghani-v@kaums.ac.ir

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Kashan University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Kashan University of Medical Sciences

##### Full name of responsible person

Dr. Vahid Dehghani

##### Position

resident

##### Latest degree

Medical doctor

##### Other areas of specialty/work

Neurology

##### Street address

Qutb Rawandi Blvd

##### City

kashan

##### Province

Isfahan

##### Postal code

8715973474

**Phone**

55443022-031

**Email**

dehghani-v@kaums.ac.ir

## Person responsible for scientific inquiries

**Contact**

**Name of organization / entity**

Kashan University of Medical Sciences

**Full name of responsible person**

Dr. Vahid Dehghani

**Position**

resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Neurology

**Street address**

Qutb Rawandi Blvd

**City**

kashan

**Province**

Isfahan

**Postal code**

8715973474

**Phone**

55443022-031

**Email**

dehghani-v@kaums.ac.ir

## Person responsible for updating data

**Contact**

**Name of organization / entity**

Kashan University of Medical Sciences

**Full name of responsible person**

Dr. Vahid Dehghani

**Position**

resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Neurology

**Street address**

Qutb Rawandi Blvd

**City**

kashan

**Province**

Isfahan

**Postal code**

8715973474

**Phone**

55443022-031

**Email**

dehghani-v@kaums.ac.ir

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

There is no further information.

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available